UGT8 (UDP-glycosyltransferase 8) is a ceramide galactosyltransferase that catalyzes the transfer of galactose from UDP-galactose to ceramide, a critical step in galactosylceramide biosynthesis 1. This enzymatic activity produces sphingolipids essential for myelin membrane composition in the central and peripheral nervous systems 1. Beyond its classical neurological role, UGT8 regulates sulfatide metabolism, which has emerged as metabolically important in various disease contexts. In cancer biology, UGT8 expression is elevated in multiple malignancies. In non-small cell lung cancer (NSCLC), SOX9-mediated UGT8 upregulation promotes glycolysis and maintains malignancy 2. Similarly, in basal-like breast cancer, UGT8 activates integrin αVβ5-mediated signaling through sulfatide production, and zoledronic acid inhibits UGT8 to suppress progression 3. UGT8 inhibition also suppresses intraductal papillary mucinous neoplasm-derived pancreatic cancer through altered mitochondrial respiration and apoptosis activation 4, and colorectal cancer through sulfatide-dependent BAX mitochondrial localization 5. In aging, UGT8 expression correlates with glycolipid accumulation in kidney tissue, with UGT8 inhibition reducing inflammatory cytokine expression 6. These findings identify UGT8 as a druggable target with therapeutic potential across multiple cancer types.